{"id":22934,"date":"2024-03-13T09:20:40","date_gmt":"2024-03-13T08:20:40","guid":{"rendered":"https:\/\/mabdesign.fr\/?p=22934"},"modified":"2025-03-27T11:08:20","modified_gmt":"2025-03-27T10:08:20","slug":"antibody-drug-conjugates","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/","title":{"rendered":"antibody-drug conjugates"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Every month, MabDesign’s market analyses give you an overview of the market and its projects<\/span> in development for a given indication or technology, to help you better understand the constantly evolving market of biologics and biomanufacturing. This month is focused on antibody-drug conjugates (or ADC). <\/em><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Antibody-drug conjugates<\/strong> have made considerable progress in recent years and are currently enjoying phenomenal success in the medical and pharmaceutical world. By combining cytotoxic drugs withtumor antigen-specific antibodies<\/strong>, these innovative biotherapies can selectively target and destroy cancer cells. Unlike more conventional approaches, such as chemotherapy for example, this approach minimizes damage to surrounding healthy tissue.<\/p>\n

Currently, 13 ADCs have been approved<\/strong> by the Food and Drug Administration, and over 1,100 candidates are in the pipeline<\/strong>, developed by 573 players.<\/p>\n

Less than 30%<\/strong> of products in development have entered the clinical phase<\/strong>. The vast majority of projects target oncology<\/strong> indications, as illustrated by the top 3 targeted indications: non-small cell lung cancer, HER2-positive or triple-negative breast cancer (TNBC). <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
products on the market<\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
products in development<\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
companies <\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

antibody-drug conjugates in development: active pipeline<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
<\/h5><\/div>\n\t\t
\n\t\t\t<\/canvas>\n\t\t<\/div>\n\n\t\t<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Top 3 indications<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"anticorps\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Dynamics<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
new** ADCs in 2022<\/div>\t\t\t
\n\t\t\t\t<\/span>\n\t\t\t\t0<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

* Indications “Solid Tumor not defined” are not included in this analysis<\/span><\/p>\n

**Entering the pipeline in the “discovery” or “preclinical” categories<\/span><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Recent deals in immunoconjugates also demonstrate the dynamic nature of this market. 4 of the 10 biggest deals recorded in 2023 involved players developing ADCs<\/strong> Pfizer acquires Seagen, an ADC expert, for $43 billion Merck signs massive partnership agreement with Daiichi Sankyo for $22 billion Abbvie acquires Immunogen, enriching its product portfolio for $10 billion, and BMS and SystImmune collaborate on the development of ADC for $8 billion.<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

Recent deals (2023)<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"pfizer\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Pfizer Inc. acquires Seagen Inc, a global biotechnology company that discovers, develops and markets transformative cancer drugs. The company’s total value is around $43 billion.<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"ADC,\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Merck signs massive partnership agreement with Daiichi Sankyo for $22 billion. <\/span>Merck will pay Daiichi for the rights to three ADCs in development. <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"ADC,\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

AbbVie has entered into a definitive agreement to acquire ImmunoGen for $10.1 billion on November 30, 2023. AbbVie thus acquires ELAHERE\u00ae, ImmunoGen’s flagship cancer therapy. <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"systimmune,\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Bristol Myers Squibb and SystImmune have agreed to jointly develop and commercialize BL-B01D1, a bispecific antibody drug conjugate for solid tumors, in a deal worth up to $8 billion. <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Download our infographic<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Antibody conjugate pipeline (ADCs)<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"ADCs,\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
<\/path><\/svg><\/span>Download in .pdf format<\/span><\/span><\/small><\/span><\/a>\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Want to find out more? <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

MabDesign has acquired and cultivates its expertise in all market segments associated with biopharmaceuticals and biomanufacturing. Our team<\/a> of consultants is at your disposal to support you in all your biotherapy-related projects. Feel free to explore our range of services<\/a>, including our marketing and strategic analyses<\/a>, if you’d like to find out more!<\/i><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tContact us<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Sources: MabDesign, GlobalData<\/p>\n

Date – March 2024<\/span><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

This month’s MabDesign market analysis gives you an overview of the antibody-drug conjugates market and projects in development. <\/p>\n","protected":false},"author":4,"featured_media":22904,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[88,119],"tags":[136,99,163,90,137,138,255],"class_list":["post-22934","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bio-hub-en","category-market-analysis-en","tag-adc-en","tag-antibodies","tag-biomedicaments-en","tag-biopharmaceuticals","tag-immunoconjugates","tag-radioconjugates","tag-therapeutic-antibodies-and-proteins"],"yoast_head":"\nantibody-drug conjugates - MabDesign<\/title>\n<meta name=\"description\" content=\"The MabDesign market analysis gives you an overview of the antibody-drug conjugates (ADCs) market: products in development, dynamics, players, deals, etc.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"antibody-drug conjugates - MabDesign\" \/>\n<meta property=\"og:description\" content=\"The MabDesign market analysis gives you an overview of the antibody-drug conjugates (ADCs) market: products in development, dynamics, players, deals, etc.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-13T08:20:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-27T10:08:20+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/ADC-January24.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1500\" \/>\n\t<meta property=\"og:image:height\" content=\"2000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anabelle Perrier\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anabelle Perrier\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/\"},\"author\":{\"name\":\"Anabelle Perrier\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/4643f9d895805d8377e2471c8e4d6918\"},\"headline\":\"antibody-drug conjugates\",\"datePublished\":\"2024-03-13T08:20:40+00:00\",\"dateModified\":\"2025-03-27T10:08:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/\"},\"wordCount\":444,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/ADC-January24.jpg\",\"keywords\":[\"ADC\",\"antibodies\",\"biom\u00e9dicaments\",\"biopharmaceuticals\",\"immunoconjugates\",\"radioconjugates\",\"Therapeutic antibodies and proteins\"],\"articleSection\":[\"Bio-hub\",\"Market analysis\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/\",\"name\":\"antibody-drug conjugates - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/ADC-January24.jpg\",\"datePublished\":\"2024-03-13T08:20:40+00:00\",\"dateModified\":\"2025-03-27T10:08:20+00:00\",\"description\":\"The MabDesign market analysis gives you an overview of the antibody-drug conjugates (ADCs) market: products in development, dynamics, players, deals, etc.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/ADC-January24.jpg\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/ADC-January24.jpg\",\"width\":1500,\"height\":2000,\"caption\":\"ADCs, market analysis, analyse march\u00e9, anticorps conjugu\u00e9s, anticorps arm\u00e9s, monoclonal antibody conjugated, immunoconjugu\u00e9s\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"antibody-drug conjugates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/4643f9d895805d8377e2471c8e4d6918\",\"name\":\"Anabelle Perrier\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f3a0b000cbed04b58d93c3453cafdf5ef34c998ff91ba6a81b173a075a0bfae2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f3a0b000cbed04b58d93c3453cafdf5ef34c998ff91ba6a81b173a075a0bfae2?s=96&d=mm&r=g\",\"caption\":\"Anabelle Perrier\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/anabelle-perriermabdesign-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"antibody-drug conjugates - MabDesign","description":"The MabDesign market analysis gives you an overview of the antibody-drug conjugates (ADCs) market: products in development, dynamics, players, deals, etc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/","og_locale":"en_US","og_type":"article","og_title":"antibody-drug conjugates - MabDesign","og_description":"The MabDesign market analysis gives you an overview of the antibody-drug conjugates (ADCs) market: products in development, dynamics, players, deals, etc.","og_url":"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/","og_site_name":"MabDesign","article_published_time":"2024-03-13T08:20:40+00:00","article_modified_time":"2025-03-27T10:08:20+00:00","og_image":[{"width":1500,"height":2000,"url":"http:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/ADC-January24.jpg","type":"image\/jpeg"}],"author":"Anabelle Perrier","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Anabelle Perrier","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/"},"author":{"name":"Anabelle Perrier","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/4643f9d895805d8377e2471c8e4d6918"},"headline":"antibody-drug conjugates","datePublished":"2024-03-13T08:20:40+00:00","dateModified":"2025-03-27T10:08:20+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/"},"wordCount":444,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/ADC-January24.jpg","keywords":["ADC","antibodies","biom\u00e9dicaments","biopharmaceuticals","immunoconjugates","radioconjugates","Therapeutic antibodies and proteins"],"articleSection":["Bio-hub","Market analysis"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/","url":"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/","name":"antibody-drug conjugates - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/ADC-January24.jpg","datePublished":"2024-03-13T08:20:40+00:00","dateModified":"2025-03-27T10:08:20+00:00","description":"The MabDesign market analysis gives you an overview of the antibody-drug conjugates (ADCs) market: products in development, dynamics, players, deals, etc.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/ADC-January24.jpg","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/04\/ADC-January24.jpg","width":1500,"height":2000,"caption":"ADCs, market analysis, analyse march\u00e9, anticorps conjugu\u00e9s, anticorps arm\u00e9s, monoclonal antibody conjugated, immunoconjugu\u00e9s"},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/antibody-drug-conjugates\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"antibody-drug conjugates"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/4643f9d895805d8377e2471c8e4d6918","name":"Anabelle Perrier","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f3a0b000cbed04b58d93c3453cafdf5ef34c998ff91ba6a81b173a075a0bfae2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f3a0b000cbed04b58d93c3453cafdf5ef34c998ff91ba6a81b173a075a0bfae2?s=96&d=mm&r=g","caption":"Anabelle Perrier"},"url":"https:\/\/mabdesign.fr\/en\/author\/anabelle-perriermabdesign-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/22934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=22934"}],"version-history":[{"count":6,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/22934\/revisions"}],"predecessor-version":[{"id":23661,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/22934\/revisions\/23661"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/22904"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=22934"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=22934"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=22934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}